<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Argatroban, a specific thrombin inhibitor, has been shown to reduce ischemic lesion size after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, recombinant tissue plasminogen activator (rtPA) has been shown to reduce ischemic lesion size in both rats and humans if given within 3 hours of symptom <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that the administration of argatroban with rtPA could extend the treatment window of <z:hpo ids='HP_0001297'>stroke</z:hpo> to 4 hours without increasing gross <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> rates or reducing efficacy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Male Wistar rats were subjected to middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion by a single fibrin-rich clot </plain></SENT>
<SENT sid="4" pm="."><plain>After embolization, rats were administered argatroban at the following dose levels: 2.08, 6.25, and 18.75 microgram  </plain></SENT>
<SENT sid="5" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="6" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="7" pm="."><plain>In a second experiment, rats received argatroban (6.25 microgram  </plain></SENT>
<SENT sid="8" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="9" pm="."><plain>min(-1)) or argatroban in combination with rtPA 4 hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="10" pm="."><plain>Tissue sections were then analyzed for lesion volume, gross <z:mp ids='MP_0001914'>hemorrhage</z:mp> and <z:mpath ids='MPATH_179'>fibrin deposition</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>RESULTS: The 6.25 microgram </plain></SENT>
<SENT sid="12" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="13" pm="."><plain>min(-1) dose demonstrated a significant reduction (P&lt;0.05) in lesion volume after 48 hours (27.2+/-6.3%) compared with controls (35.3+/-3.7%) </plain></SENT>
<SENT sid="14" pm="."><plain>A significant reduction (P&lt;0.05) in lesion volume was observed in the argatroban-plus-rtPA group (17.1+/-10.4%) compared with controls (35.3+/-3.7%) </plain></SENT>
<SENT sid="15" pm="."><plain>No increase in hemorrhagic transformation was observed </plain></SENT>
<SENT sid="16" pm="."><plain><z:mpath ids='MPATH_179'>Fibrin deposition</z:mpath> in the ipsilateral cortical microvasculature was significantly decreased in the 4-hour combination argatroban-plus-rtPA group compared with the controls (P&lt;0.05) </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSIONS: This study demonstrates that the combination of argatroban and rtPA extends the window of opportunity for treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> to 4 hours without increasing hemorrhagic transformation </plain></SENT>
</text></document>